New UK Study: Medical Cannabis Reduces Opioid Dependency by 38%
A peer-reviewed study published in the British Journal of Clinical Pharmacology has found that patients prescribed cannabis-based medicinal products reduced their opioid consumption by an average of 38% over a six-month period. The research, conducted across five UK pain clinics, adds to a growing body of evidence supporting medical cannabis as an opioid-sparing intervention for chronic pain patients.
Landmark UK Study Links Medical Cannabis to Opioid Reduction
A peer-reviewed clinical study published in the British Journal of Clinical Pharmacology has found that patients who were prescribed cannabis-based medicinal products (CBMPs) alongside their existing pain management regimens reduced their opioid consumption by an average of 38% over a six-month observation period. The study is one of the largest of its kind conducted exclusively within the UK healthcare system.
Study Design and Methodology
The research tracked 412 patients across five NHS pain clinics and two private prescribing centres. Participants had documented opioid dependency linked to chronic pain conditions including neuropathic pain, fibromyalgia, and post-surgical pain. All patients were prescribed THC/CBD combination oil preparations alongside their existing treatment plan. Opioid dosage was monitored via prescription records and patient self-reporting at monthly intervals.
At the six-month mark, 38% of participants had measurably reduced their opioid consumption, with 14% discontinuing opioids entirely. Quality of life scores, measured using the EQ-5D-5L tool, improved in 71% of participants.
Clinical Significance
The UK faces a significant opioid prescribing crisis, with over 5.6 million opioid prescriptions dispensed annually. Long-term opioid use carries substantial risks including tolerance, physical dependence, respiratory depression, and increased mortality. The prospect of a well-tolerated adjunct therapy that reduces opioid burden has considerable public health implications.
Lead researcher Dr Sarah Merton of the UCL School of Pharmacy noted: "These results align with data from Canada and the United States, where medical cannabis programmes have been associated with reduced opioid prescribing. UK-specific evidence has been limited until now."
What This Means for Patients
Patients currently prescribed opioids for chronic pain who are interested in exploring medical cannabis as an adjunct should speak to their specialist or consider a consultation with a registered private medical cannabis clinic. Costs vary significantly between providers; comparing options can reduce ongoing prescription expenses considerably.
